EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Efficacy and safety of intraoperative hyperthermic intraperitoneal chemotherapy for locally advanced colorectal cancer (HIPECT4): final analysis of randomized clinical trial

Wirksamkeit und Sicherheit der intraoperativen hyperthermen intraperitonealen Chemotherapie bei lokal fortgeschrittenem kolorektalem Karzinom (HIPECT4): Endauswertung einer randomisierten klinischen Studie

Alvaro Arjona-Sánchez, Alberto Gutiérrez-Calvo, Juan J Segura-Sampedro, Rafael Morales, Estibalitz Pérez-Viejo, Vanessa Concepción-Martín, Susana Sánchez-García, Alfonso García-Fadrique, Isabel Prieto-Nieto, Lana Bijelic, Juan Torres-Melero, Maria Ramirez-Faraco und 16 weitere

BJS Open · 05.03.2026 · 10 (2)

DOI: 10.1093/bjsopen/zrag002 ↗

Auf einen Blick

Bei 184 Patient:innen mit resezierbarem klinischem T4 N0-2M0-Kolonkarzinom war mitmitomycin-C-basierte HIPEC mit besserer lokoregionärer Kontrolle verbunden als die Standardbehandlung. Gesamtüberleben und krankheitsfreies Überleben unterschieden sich nicht.

Fragestellung

Verbessert intraoperative HIPEC mit Mitomycin C bei lokal fortgeschrittenem Kolonkarzinom die lokoregionäre Kontrolle im Vergleich zur Standardbehandlung?

Methode

Randomisierte klinische Studie; 1:1-Zuteilung zwischen November 2015 und März 2021; Vergleich von adjuvanter HIPEC mit Mitomycin C (30 mg/m2, 60 Minuten) mit Standardbehandlung; Follow-up 36 Monate.

Ergebnisse

184 Patient:innen. Lokoregionäre Kontrolle: hazard ratio 0,19 (95 %-KI 0,04–0,86; P = 0,031). Für pT4-Kolonkarzinom: hazard ratio 0,08 (95 %-KI 0,01–0,65; P = 0,017).

Schlussfolgerung der Autor:innen

Die langfristige Auswertung zeigte, dass mitomycin-C-basierte HIPEC die peritoneale Rezidivrate senkte, ohne die Toxizität zu erhöhen. Ein Unterschied bei Gesamtüberleben und krankheitsfreiem Überleben bestand nicht.

Kernaussagen

  • Bessere lokoregionäre Kontrolle mit HIPEC
  • Kein Unterschied bei Gesamt- und krankheitsfreiem Überleben
  • Weniger peritoneale Rezidive, ohne erhöhte Toxizität

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift BJS Open, online erschienen am 27.03.2026. Verfasst von Alvaro Arjona-Sánchez und 27 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Oncologic and Pancreatic Surgery, University Hospital Reina Sofía, Córdoba, Spain. Hauptthemen laut MEDLINE: Hyperthermic Intraperitoneal Chemotherapy, Colorectal Neoplasms, Mitomycin, Peritoneal Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Public Health System, FIBICO-Consejería Salud Junta de Andalucía 2018, Spanish Association of Surgeons (AEC) 2010.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite adjuvant systemic chemotherapy after surgical resection in patients with pT4 stage colon cancer, a high percentage of them will develop peritoneal metastases. Intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment option with the goal of preventing metachronous peritoneal metastases. The aim of this study was to report the longer-term outcomes of peritoneal control with the use of intraoperative HIPEC based on mitomycin C after the last enrolled patient of the HIPECT4 trial reached 36 months follow-up.

Methods

Between November 2015 and March 2021, patients with resectable primary clinical T4 N0-2M0 were included and randomized (1:1) to either adjuvant HIPEC with mitomycin C (30 mg/m2, 60 minutes) or standard treatment. The primary endpoint was locoregional control at 36 months. Kaplan–Meier survival analysis with a log-rank test was used to compare the two study groups.

Results

A total of 184 patients were included and followed up at 36 months. The locoregional control rate was improved with HIPEC compared with adjuvant chemotherapy alone (hazard ratio 0.19, 95% confidence interval 0.04 to 0.86; P = 0.031). Three years overall survival and disease-free survival did not differ between patients assigned to the HIPEC and control groups. Subgroup analysis showed better locoregional control with the use of HIPEC for patients with definitive pT4 colon cancer (hazard ratio 0.08, 0.01 to 0.65; P = 0.017) and per protocol (receiving adjuvant chemotherapy) patients (hazard ratio 0.18, 0.04 to 0.83; P = 0.028). The pattern of recurrence was modified significantly using HIPEC with less peritoneal relapse.

Conclusion

The long-term outcome analysis of the HIPECT4 trial demonstrated that using mitomycin C-based HIPEC reduced peritoneal recurrence in patients with locally advanced colon cancer without increasing toxicity. However, there was no difference in overall survival and disease-free survival. Registration number NCT02614534 (https://clinicaltrials.gov/).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hyperthermic Intraperitoneal ChemotherapyColorectal NeoplasmsMitomycinPeritoneal NeoplasmsHyperthermia, InducedHumansFemaleMaleMiddle AgedChemotherapy, AdjuvantAgedTreatment OutcomeNeoplasm StagingIntraoperative CareKaplan-Meier EstimateDisease-Free SurvivalCombined Modality Therapy

Substanzen

Mitomycin

Autor:innen und Institutionen

  • Unit of Oncologic and Pancreatic Surgery, University Hospital Reina Sofía, Córdoba, Spain.
  • Maimónides Biomedical Research Institute of Córdoba (IMIBIC)/Reina Sofia University Hospital/University of Córdoba, Cordoba, Spain.
  • Unit of Peritoneal Oncologic Surgery, Surgery Department, Hospital Príncipe de Asturias, Alcalá de Henares, Madrid, Spain.
  • General & Digestive Surgery Service, Hospital Universitario Son Espases, Palma de Mallorca, Spain.
  • School of Medicine, Universidad CEU San Pablo, 28003 Madrid, Spain.
  • General & Digestive Surgery Service, Hospital Universitario La Paz, Madrid, Spain.

Förderung

  • Public Health System
  • FIBICO-Consejería Salud Junta de Andalucía 2018
  • Spanish Association of Surgeons (AEC) 2010

Zitieren

APA

Arjona-Sánchez, A., Gutiérrez-Calvo, A., Segura-Sampedro, J. J., Morales, R., Pérez-Viejo, E., Concepción-Martín, V., Sánchez-García, S., García-Fadrique, A., Prieto-Nieto, I., Bijelic, L., Torres-Melero, J., Ramirez-Faraco, M., Prada-Villaverde, A., Carrasco-Campos, J., Artiles-Armas, M., Villarejo-Campos, P., Ortega-Pérez, G., Boldo-Roda, E., Sánchez-Hidalgo, J. M., …, & Rufián-Peña, S. (2026). Efficacy and safety of intraoperative hyperthermic intraperitoneal chemotherapy for locally advanced colorectal cancer (HIPECT4): final analysis of randomized clinical trial. BJS Open, 10(2). https://doi.org/10.1093/bjsopen/zrag002

Vancouver

Arjona-Sánchez A, Gutiérrez-Calvo A, Segura-Sampedro JJ, Morales R, Pérez-Viejo E, Concepción-Martín V, et al. Efficacy and safety of intraoperative hyperthermic intraperitoneal chemotherapy for locally advanced colorectal cancer (HIPECT4): final analysis of randomized clinical trial. BJS Open. 2026;10(2). doi:10.1093/bjsopen/zrag002

BibTeX
@article{ArjonaSnchez2026,
  author = {Arjona-Sánchez, Alvaro and Gutiérrez-Calvo, Alberto and Segura-Sampedro, Juan J and Morales, Rafael and Pérez-Viejo, Estibalitz and Concepción-Martín, Vanessa and Sánchez-García, Susana and García-Fadrique, Alfonso and Prieto-Nieto, Isabel and Bijelic, Lana and Torres-Melero, Juan and Ramirez-Faraco, Maria and Prada-Villaverde, Arancha and Carrasco-Campos, Joaquin and Artiles-Armas, Manuel and Villarejo-Campos, Pedro and Ortega-Pérez, Gloria and Boldo-Roda, Enrique and Sánchez-Hidalgo, Juan M and Casado-Adam, Angela and Rodríguez-Ortiz, Lidia and Rufian-Andújar, Blanca and Aranda, Enrique and Cano-Osuna, Maria T and Díaz-López, Cesar and Romero-Ruiz, Antonio and Vazquez-Borrego, Maria Carmen and Rufián-Peña, Sebastian},
  title = {Efficacy and safety of intraoperative hyperthermic intraperitoneal chemotherapy for locally advanced colorectal cancer (HIPECT4): final analysis of randomized clinical trial},
  journal = {BJS Open},
  year = {2026},
  volume = {10},
  number = {2},
  doi = {10.1093/bjsopen/zrag002}
}
Kostenlos starten →